2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Cites (233)

Items 201–233 of 233

1. Effect of proprotein convertase subtilisin/kexin type 9 ( <scp>PCSK9</scp> ) monoclonal antibodies on new‐onset diabetes mellitus and glucose metabolism: <scp>A</scp> systematic review and meta‐analysis
   Cao, Ye‐Xuan, Liu, Hui‐Hui, Dong, Qiu‐Ting, Li, Sha, Li, Jian‐Jun · 2018 · Diabetes, Obesity and Metabolism
2. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes
   Khan, Safi U, Talluri, Swapna, Riaz, Haris, Rahman, Hammad, Nasir, Fahad, Bin Riaz, Irbaz, Sattur, Sudhakar, Ahmed, Haitham, Kaluski, Edo, Krasuski, Richard · 2018 · European Journal of Preventive Cardiology
3. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials
   Saha, Sandeep A., Arora, Rohit R. · 2010 · International Journal of Cardiology
4. Combination statin-fibrate therapy: safety aspects
   Franssen, R., Vergeer, M., Stroes, E. S. G., Kastelein, J. J. P. · 2009 · Diabetes, Obesity and Metabolism
5. The contribution of GWAS loci in familial dyslipidemias
   Ripatti, Pietari, Rämö, Joel T., Söderlund, Sanni, Surakka, Ida, Matikainen, Niina, Pirinen, Matti, Pajukanta, Päivi, Sarin, Antti-Pekka, Service, Susan K., Laurila, Pirkka-Pekka et al. · 2016 · PLOS Genetics
6. Explaining the decline in coronary heart disease mortality in Portugal between 1995 and 2008
   Pereira, Marta, Azevedo, Ana, Lunet, Nuno, Carreira, Helena, O’Flaherty, Martin, Capewell, Simon, Bennett, Kathleen · 2013 · Circulation: Cardiovascular Quality and Outcomes
7. Statin adherence is associated with reduced recurrent stroke risk in patients with or without atrial fibrillation
   Flint, Alexander C., Conell, Carol, Ren, Xiushui, Kamel, Hooman, Chan, Sheila L., Rao, Vivek A., Johnston, S. Claiborne · 2017 · Stroke
8. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF
   Feinstein, Matthew J., Jhund, Pardeep, Kang, Joseph, Ning, Hongyan, Maggioni, Aldo, Wikstrand, John, Kjekshus, John, Tavazzi, Luigi, McMurray, John, Lloyd-Jones, Donald M. · 2015 · European Journal of Heart Failure
9. Usefulness of non-high-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men in 22-year follow-up
   Harari, Gil, Green, Manfred S., Magid, Avi, Zelber-Sagi, Shira · 2017 · The American Journal of Cardiology
10. Statins and renovascular disease in the elderly: a population-based cohort study
    Hackam, D. G., Wu, F., Li, P., Austin, P. C., Tobe, S. W., Mamdani, M. M., Garg, A. X. · 2011 · European Heart Journal
11. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    on behalf of the FIELD Study Investigators, d’Emden, Michael C., Jenkins, Alicia J., Li, Liping, Zannino, Diana, Mann, Kristy P., Best, James D., Stuckey, Bronwyn G. A., Park, Kris, Saltevo, Juha et al. · 2014 · Diabetologia
12. Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol &lt;70 mg/dL compared with a novel low-density lipoprotein estimation method
    Whelton, Seamus P., Meeusen, Jeffrey W., Donato, Leslie J., Jaffe, Allan S., Saenger, Amy, Sokoll, Lori J., Blumenthal, Roger S., Jones, Steven R., Martin, Seth S. · 2017 · Journal of Clinical Lipidology
13. Niemann-Pick C1-Like 1 (NPC1L1) inhibition and cardiovascular diseases
    Pirillo, A., L. Catapano, A., D. Norata, G. · 2016 · Current Medicinal Chemistry
14. How well can we control dyslipidemias through lifestyle modifications?
    Riccardi, Gabriele, Vaccaro, Olga, Costabile, Giuseppina, Rivellese, Angela A. · 2016 · Current Cardiology Reports
15. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use
    Holoshitz, Noa, Alsheikh-Ali, Alawi A., Karas, Richard H. · 2008 · The American Journal of Cardiology
16. Natural<i>trans</i>fat, dairy fat, partially hydrogenated oils, and cardiometabolic health: the Ludwigshafen Risk and Cardiovascular Health Study: Table 1
    Mozaffarian, Dariush · 2016 · European Heart Journal
17. Association between cardiac rehabilitation participation and health status outcomes after acute myocardial infarction
    Kureshi, Faraz, Kennedy, Kevin F., Jones, Philip G., Thomas, Randal J., Arnold, Suzanne V., Sharma, Praneet, Fendler, Timothy, Buchanan, Donna M., Qintar, Mohammed, Ho, P. Michael et al. · 2016 · JAMA Cardiology
18. Colesevelam for type 2 diabetes mellitus: an abridged Cochrane review
    Ooi, C. P., Loke, S. C. · 2014 · Diabetic Medicine
19. Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis
    Navarese, Eliano P., Gurbel, Paul A., Andreotti, Felicita, Kołodziejczak, Michalina Marta, Palmer, Suetonia C., Dias, Sofia, Buffon, Antonino, Kubica, Jacek, Kowalewski, Mariusz, Jadczyk, Tomasz et al. · 2017 · PLOS ONE
20. No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: a meta-analysis of randomized controlled trials
    Al-Gobari, Muaamar, Le, Hai-Ha, Fall, Mor, Gueyffier, François, Burnand, Bernard · 2017 · PLOS ONE
21. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial
    Stroes, Erik S.G., Susekov, Andrey V., de Bruin, Tjerk W.A., Kvarnström, Mats, Yang, Hong, Davidson, Michael H. · 2018 · Journal of Clinical Lipidology
22. Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL)
    Arsenault, Benoit J., Boekholdt, S. Matthijs, Mora, Samia, DeMicco, David A., Bao, Weihang, Tardif, Jean-Claude, Amarenco, Pierre, Pedersen, Terje, Barter, Philip, Waters, David D. · 2014 · The American Journal of Cardiology
23. Effect modifications of lipid-lowering therapy on progression of aortic stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study)
    Greve, Anders M., Bang, Casper N., Boman, Kurt, Egstrup, Kenneth, Forman, Julie L., Kesäniemi, Y. Antero, Ray, Simon, Pedersen, Terje R., Best, Patricia, Rajamannan, Nalini M. et al. · 2018 · The American Journal of Cardiology
24. Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases
    Corrao, Giovanni, Scotti, Lorenza, Zambon, Antonella, Baio, Gianluca, Nicotra, Federica, Conti, Valentino, Capri, Stefano, Tragni, Elena, Merlino, Luca, Catapano, Alberico L. et al. · 2011 · Atherosclerosis
25. LDL-cholesterol measurement in diabetic type 2 patients: a comparison between direct assay and popular equations
    Razi, Farideh, Forouzanfar, Katayoon, Bandarian, Fatemeh, Nasli-Esfahani, Ensieh · 2017 · Journal of Diabetes &amp; Metabolic Disorders
26. The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations
    Agarwala, Anandita, Jones, Peter, Nambi, Vijay · 2015 · Current Atherosclerosis Reports
27. The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin
    Shaw, Steven M., Chaggar, Parminder, Ritchie, James, Shah, Mohammed K. H., Baynes, Anna C., O’Neill, Nicola, Fildes, James E., Yonan, Nizar, Williams, Simon G. · 2009 · Transplantation
28. Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: a nationwide survey of 2674 individuals in Hungary
    Mark, Laszlo, Vallejo-Vaz, Antonio J., Reiber, Istvan, Paragh, György, Kondapally Seshasai, Sreenivasa Rao, Ray, Kausik K. · 2015 · Atherosclerosis
29. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men
    Peura, Piia, Martikainen, Janne, Soini, Erkki, Hallinen, Taru, Niskanen, Leo · 2008 · Current Medical Research and Opinion
30. Use of coronary artery calcium testing to improve coronary heart disease risk assessment in a lung cancer screening population: the Multi-Ethnic Study of Atherosclerosis (MESA)
    Garg, Parveen K., Jorgensen, Neal W., McClelland, Robyn L., Leigh, J. Adam, Greenland, Philip, Blaha, Michael J., Yoon, Andrew J., Wong, Nathan D., Yeboah, Joseph, Budoff, Matthew J. · 2018 · Journal of Cardiovascular Computed Tomography
31. Effect of acute exogenous hyperinsulinaemia on very low density lipoprotein subfraction composition in normal subjects
    Annuzzi, G., Iovine, C., Mandarino, B., Patti, L., Di Marino, L., Riccardi, G., Rivellese, A. A. · 2001 · European Journal of Clinical Investigation
32. Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
    Pokharel, Yashashwi, Chinnakondepalli, Khaja, Vilain, Katherine, Wang, Kaijun, Mark, Daniel B., Davies, Glenn, Blazing, Michael A., Giugliano, Robert P., Braunwald, Eugene, Cannon, Christopher P. et al. · 2017 · Circulation: Cardiovascular Quality and Outcomes
33. Cholesterol and Heart Failure
    Francis, Gary S. · 2017 · Journal of the American College of Cardiology